ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0464

Association Between CKD and New Onset of Dyslipidemia: Results from a Longitudinal Nationwide Survey

Session Information

Category: CKD (Non-Dialysis)

  • 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention


  • Kosugi, Takaaki, Nara Medical University, Kashihara, Nara, Japan
  • Eriguchi, Masahiro, Nara Medical University, Kashihara, Nara, Japan
  • Yoshida, Hisako, Osaka City University Graduate School of Medicine School of Medicine, Osaka, Osaka, Japan
  • Tasaki, Hikari, Nara Medical University, Kashihara, Nara, Japan
  • Nishimoto, Masatoshi, Nara Medical University, Kashihara, Nara, Japan
  • Kasahara, Masato, Institute for Clinical and Translational Science Nara Medical University Hospital, Kashiara, Nara, Japan
  • Iseki, Kunitoshi, Nakamura Clinic, Urazoe, Okinawa, Japan
  • Asahi, Koichi, Iwate Medical University, Morioka, Iwate, Japan
  • Yamagata, Kunihiro, University of Tsukuba, Tsukuba, Ibaraki, Japan
  • Konta, Tsuneo, Yamagata University Graduate School of Medical Science, Yamagata, Yamagata, Japan
  • Fujimoto, Shouichi, University of Miyazaki, Miyazaki, Miyazaki, Japan
  • Narita, Ichiei, Niigata University, Niigata, Niigata, Japan
  • Shibagaki, Yugo, St Marianna University Hospital, Kawasaki, Kanagawa, Japan
  • Moriyama, Toshiki, Osaka University Health Care Center, Suita, Osaka, Japan
  • Kondo, Masahide, University of Tsukuba, Tsukuba, Ibaraki, Japan
  • Watanabe, Tsuyoshi, Fukushima Medical University School of Medicine, Fukushima, Fukushima, Japan
  • Tsuruya, Kazuhiko, Nara Medical University, Kashihara, Nara, Japan

Dyslipidemia is a significant risk factor of CVD and seems to be associated with CKD onset and progression. On the contrary, CKD patients have dyslipidemia more frequently than non-CKD patients, but it is unclear whether CKD affects new onset of dyslipidemia.


This is a longitudinal study based on data obtained from the Japanese Specific Health Check and Guidance System. Among 664,926 individuals who participated in this program from 2008 to 2014, we excluded participants who met the following criteria: 1) health check only one time, 2) missing values for creatinine or proteinuria, 3) dyslipidemia at baseline, or 4) medication for dyslipidemia at any point. We evaluated new onset of dyslipidemia according to each factor; hypertriglyceridemia (High-TG), hyper-LDL cholesterolemia (High-LDL), or hypo-HDL cholesterolemia (Low-HDL), defined as triglycerides ≥150 mg/dL, LDL cholesterol ≥140 mg/dL, or HDL cholesterol <40 mg/dL, respectively, and compared between participants with and without CKD. These associations were analyzed using Kaplan-Meier methods and Cox regression analysis after adjustment for clinically relevant factors.


During a median follow-up period of 3.1 years, the cumulative incidences of High-TG, High-LDL, and Low-HDL were 45,300, 51,940, and 13,313 participants, respectively, among 305,893 participants (non-CKD: 254,884; CKD: 51,009). In the univariable analyses, hazard ratios (HRs) [95% confidence intervals (CIs)] in CKD vs non-CKD participants were 1.31 [1.27-1.34], 1.02 [0.99-1.05], and 1.70 [1.63-1.77] for High-TG, High-LDL, and Low-HDL, respectively. After adjustment for clinically relevant confounders, adjusted HRs [95% CIs] in CKD participants were 1.10 [1.07-1.13], 0.99 [0.96-1.02], and 1.16 [1.11-1.22] for High-TG, High-LDL, and Low-HDL, respectively.


CKD was associated with new onset of High-TG and Low-HDL, but not High-LDL among general population in Japan.